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Abstract 
The COVID-19 pandemic has shifted primary care and other practices towards remote care and 
telemedicine options to minimize viral exposure. Although in-person visits are sometimes 
indispensable, research shows that telemedicine can expand access to vital services without 
sacrificing patient-centered care. 
Medication abortion is an essential, time-sensitive service that is particularly well-suited to 
telemedicine provision, including in primary care settings. Decades of clinical research and 
practice guidelines from core medical societies affirm the safety and efficacy of providing 
medication abortion remotely. Neither FDA nor professional guidelines require sonography for 
medication abortion, and research shows that necessary clinical assessments can be achieved 
without ultrasound. New practice guidelines recommend against Rh testing for abortions under 
8 weeks of pregnancy and rely on patient history for those provided from 8 to 11 weeks. 
As primary care providers, we can and should provide high-quality, low-risk abortion care for 
patients without point-of-care exams and labs. This discussion includes a detailed checklist for 
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providing such remote-care medication abortion in a variety of settings. Such strategies will 
allow more clinicians to offer this essential care both during and after the Covid-19 crisis. 
 
 
Medical systems across the US are adjusting their protocols in response to the Covid-19 
pandemic with an increasing reliance on telemedicine to manage chronic and non-urgent 
conditions. These shifts conserve scarce resources, ensure we can provide care for critically ill 
patients, and minimize viral exposure for patients and health care workers. This change in 
practice has also revealed the extent to which our medical system has traditionally been rooted 
in a model of in-person visits. While an in-person encounter can foster connection between 
patient and provider, convey essential information, and provide comfort during times of 
suffering, in many cases telemedicine can improve access as well as reduce financial and 
logistical burdens. Such benefits have already been demonstrated for remote monitoring of 
many chronic diseases, including hypertension1 and diabetes,2 as well as urgent care visits.3 
During the Covid-19 crisis, remote care options are critical for maintaining essential services, 
particularly when data shows that point-of-care assessments are not necessary to ensure 
patient safety.   
Abortion care is a key example where remote care can be integrated without compromising 
patient safety. As primary care providers and educators, we concur with the assessment of key 
professional organizations and a recent NEJM Perspective essay,4 that abortion care is a time-
sensitive and essential component of health care provision in a pandemic.5 Delays in abortion 
care, resulting from Covid-19 and new state policies, increase the risk to individuals and make 
abortion inaccessible for some. Delays of days or weeks can also change the type of abortion 
that individuals are allowed to have. Depending on the state, 10 or 11 weeks gestation is the 
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last opportunity to choose between a medication abortion (MAB) or a procedural abortion (also 
known as a manual or electric vacuum aspiration procedure). Both methods are safe and 
effective, but after 10 or 11 weeks, a procedure is the only legal option. In contrast to an 
procedural abortion, MAB can be provided with minimal physical interaction with medical 
facilities, which can be beneficial for patients during the pandemic. 
Research has demonstrated that telemedicine can be used to safely expand access to MAB.6,7 
The feasibility of integrating medication abortion into practices that do not currently offer 
procedural abortion has been demonstrated8 and primary care physicians have expressed 
willingness to provide this care.9 In 2017, 60% of individuals eligible for MAB chose this method 
and various studies have shown that many patients prefer to receive abortion services in 
primary care settings.10,11,12,13 
Primary care providers can play a vital role in meeting the need for abortion access, which has 
been subject to increased restrictions before and during the pandemic.14 However, many 
providers have had limited ability to eliminate some unnecessary but traditional MAB steps due 
to restrictive legislation or institutional policies that require in-person contact with patients. 
Medication abortion protocols often include an ultrasound to help estimate gestational age 
(EGA) and rule out an ectopic pregnancy, a blood type to determine patients’ Rh status and 
need for RhoGAM, and in some cases screening labs for anemia. However, many leaders in 
family planning research and clinical guidance, such as the National Abortion Federation (NAF), 
Society of Family Planning (SFP), and American College of Obstetricians and Gynecologists 
(ACOG), have published guidelines that demonstrate the safety and efficacy of providing MAB 
without many of these point-of-care tests. 
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For example, sonography is not required for MAB by the NAF’s clinical guidelines15 nor by FDA 
guidelines for mifepristone,16 and there is strong evidence that the necessary clinical 
assessments can be achieved without ultrasound.17 While sonography remains a standard 
method for assessing gestational age, several studies evaluating the accuracy of pregnancy 
dating by patients’ last menstrual period (LMP) concluded that such dating is comparable to 
ultrasound and highly accurate for individuals with regular periods and no consistent hormonal 
contraception use in the month prior to pregnancy.18,19,20,21,22,23 
Furthermore, ultrasound confirmation of intrauterine pregnancy location is not necessary. 
Ectopic pregnancy risk can be accurately assessed through history and exam, and patients can 
be referred for an ultrasound if found to be at risk.22 In several studies, individuals who did not 
get an ultrasound before MAB had no higher rates of adverse events related to ectopic 
pregnancy.24,25 The vast majority of pregnancies are intrauterine, and there is evidence that 
ultrasound screening for ectopic pregnancy among symptom-free patients has a high false-
positive rate and limited medical benefit.26 Given that professional guidelines for routine prenatal 
care do not mandate ultrasound screening before 11 weeks EGA for asymptomatic patients who 
wish to carry their pregnancies to term,27 there is no clear clinical justification for routinely 
screening pregnant patients under 11 weeks EGA who are choosing medication abortion.  
Based on clinical studies demonstrating a low volume of fetal blood cells in maternal circulation 
and a low risk of sensitization in patients who do not receive anti-D immune globulin in early 
pregnancy, NAF guidelines recommend against Rh testing for all abortions at less than 8 weeks 
EGA.28,29 For patients between 8 and 11 weeks EGA, providers can screen for history of Rh 
testing in previous pregnancies and only schedule in-person visits for individuals with no 
previous testing or unknown status. Hemoglobin testing to screen for anemia has not been 
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shown to improve outcomes and is recommended only when there is a high suspicion of 
anemia.30  
Some protocols and practices use ultrasound to confirm an abortion is complete. However, 
there are several other accurate modalities to assess abortion completion, including patient 
history obtained remotely or in-person, urine HCG testing, or a combination of these 
methods.31,32,33,34,35 All of these are supported by evidence and comparable to ultrasound in 
confirming MAB completion or identifying patients at risk of ongoing pregnancy. By eliminating 
the patient examination, ultrasound, and lab testing from the MAB process, and by offering 
phone or telemedicine follow-up, we can care for patients while minimizing physical contact and 
lowering risk of viral transmission.  
Qualitative studies affirm that many abortion patients prefer the privacy, lower clinical volumes, 
and geographic proximity of primary care offices,36 and these features also allow patients to 
minimize exposure risk when seeking timely and essential abortion services. The FDA labeling 
for mifepristone, one of two medications needed for MAB, requires that it be dispensed in-
person to patients. By streamlining protocols, however, we can minimize exposure risk and 
reduce the time patients must spend in health care facilities both during and after the pandemic. 
An example of a checklist that clearly outlines steps to minimize physical contact while providing 
safe and effective care can be found here.  
It is important for all people to have timely access to abortion care. As the Covid-19 crisis forces 
the medical community to develop new practices to ensure patient safety, abortion must be 
included in these discussions, to ensure optimal experiences for individuals and access to the 
care they need. Remote options for medication abortion allow clinicians to offer essential, 
patient-centered care while limiting the need for in-person visits and reducing the risk of 
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nosocomial infections. It is important to collect outcome data on the safety of MAB during this 
period, since this data may encourage primary care clinicians to offer this vital service to their 
patients even after the pandemic has resolved. 
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